Related Experiment Video
Updated: Aug 14, 2026

Morphological and Functional Assessment of the Right Ventricle Using 3D Echocardiography
Published on: October 28, 2020
Left ventricular geometry in children with mild to moderate chronic renal insufficiency
Maria Chiara Matteucci1, Elke Wühl, Stefano Picca
1Division of Pediatric Nephrology, Bambino Gesú, Hospital, Rome, Italy.
Insights
Cardiac remodeling, including left ventricular hypertrophy (LVH), is common in children with chronic renal insufficiency (CRI). Factors like male gender, anemia, and obesity, not blood pressure, are linked to LVH in pediatric kidney disease.
Area of Science:
- Pediatric Nephrology
- Cardiology
- Cardiovascular Risk Assessment
Background:
- Left ventricular hypertrophy (LVH) is a key cardiovascular risk marker in adults with chronic kidney disease (CKD).
- Cardiovascular issues are suspected in children with chronic renal insufficiency (CRI), but the timing of cardiac alterations is unclear.
Purpose of the Study:
- To determine the prevalence and associated factors of abnormal left ventricular (LV) geometry in children with stages 2-4 CKD.
- To compare cardiac alterations in children with CRI to healthy controls.
Main Methods:
- Echocardiograms, ambulatory blood pressure monitoring, and biochemical profiles were analyzed in 156 children (3-18 years) with CKD.
- LV mass was indexed to height^2.7 and compared to 133 healthy children.
- Statistical analysis identified independent correlates and predictors of LV geometry.
Main Results:
- 10.2% showed concentric LV remodeling, 12.1% concentric LVH, and 21% eccentric LVH.
- LVH was more prevalent in boys (43.3% vs. 19.4%) and independently associated with male gender and BMI.
- Low hemoglobin, low GFR, young age, and high BMI correlated with LV mass index.
- High C-reactive protein (>10 mg/dl) significantly increased the probability of abnormal LV geometry (OR 26).
Conclusions:
- Significant cardiac remodeling, both concentric and eccentric, occurs in children even at early stages of CRI.
- LVH prevalence is linked to male gender, anemia, and obesity, but not blood pressure.
- Inflammation and potentially volume status also impact cardiac geometry in pediatric CKD.
Abstract:
Left ventricular hypertrophy (LVH) is the most important independent marker of cardiovascular risk in adults with chronic kidney disease. Cardiovascular morbidity seems increased even in children with chronic renal insufficiency (CRI), but the age and stage of CRI when cardiac alterations become manifest are unknown. For assessing the prevalence and factors associated with abnormal LV geometry in children with CRI, echocardiograms, ambulatory BP monitoring, and biochemical profiles were obtained in 156 children aged 3 to 18 yr with stages 2 through 4 chronic kidney disease (GFR 49 +/- 19 ml/min per 1.73 m2) and compared with echocardiograms obtained in 133 healthy children of comparable age and gender. LV mass was indexed to height2.7. Concentric LV remodeling was observed in 10.2%, concentric LVH in 12.1%, and eccentric LVH in 21% of patients. LVH was more common in boys (43.3 versus 19.4%; P < 0.005). Probability of LVH independently increased with male gender (odds ratio [OR] 2.62; P < 0.05) and standardized body mass index (OR 1.56; P = 0.01). Low hemoglobin, low GFR, young age, and high body mass index were independent correlates of LV mass index (0.005 < P < 0.05). LV concentricity (relative wall thickness) was positively associated with serum albumin (P < 0.05). Probability of abnormal LV geometry increased with C-reactive protein >10 mg/dl (OR 26; P < 0.001). In conclusion, substantial cardiac remodeling of both concentric and eccentric type is present at young age and early stages of CRI in children. Prevalence of LVH is related to male gender, anemia, and ponderosity but not to BP. Additional effects of volume status and inflammation on cardiac geometry are also evident.
Related Concept Videos
Mitral Regurgitation I: Introduction
Mitral Stenosis I: Introduction
Mitral Stenosis II: Clinical features and Diagnostic Tests
Heart Failure II: Pathophysiology
